Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Giovanni B. Frisoni, Marina Boccardi, Frederik Barkhof, Kaj Blennow, Stefano Cappa, Konstantinos Chiotis, Jean Francois Démonet, Valentina Garibotto, Panteleimon Giannakopoulos, Anton Gietl, Oskar Hansson, Karl Herholz, Clifford R. Jack, Flavio Nobili, Agneta Nordberg, Heather M. Snyder, Mara Ten Kate, Andrea Varrone, Emiliano Albanese, Stefanie BeckerPatrick Bossuyt, Maria C. Carrillo, Chiara Cerami, Bruno Dubois, Valentina Gallo, Ezio Giacobini, Gabriel Gold, Samia Hurst, Anders Lönneborg, Karl Olof Lovblad, Niklas Mattsson, José Luis Molinuevo, Andreas U. Monsch, Urs Mosimann, Alessandro Padovani, Agnese Picco, Corinna Porteri, Osman Ratib, Laure Saint-Aubert, Charles Scerri, Philip Scheltens, Jonathan M. Schott, Ida Sonni, Stefan Teipel, Paolo Vineis, Pieter Jelle Visser, Yutaka Yasui, Bengt Winblad

Research output: Contribution to journalReview article

172 Scopus citations

Abstract

The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.

Original languageEnglish (US)
Pages (from-to)661-676
Number of pages16
JournalThe Lancet Neurology
Volume16
Issue number8
DOIs
StatePublished - Aug 2017

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers'. Together they form a unique fingerprint.

  • Cite this

    Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J. F., Garibotto, V., Giannakopoulos, P., Gietl, A., Hansson, O., Herholz, K., Jack, C. R., Nobili, F., Nordberg, A., Snyder, H. M., Ten Kate, M., Varrone, A., Albanese, E., ... Winblad, B. (2017). Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. The Lancet Neurology, 16(8), 661-676. https://doi.org/10.1016/S1474-4422(17)30159-X